Synamp’s goal is the discovery and development of entirely new classes of antibiotics capable of selectively targeting and killing bacterial cells via novel modes of action. In the FD interview Synamp illustrates the new marketpotential for the next generation of antibiotics. Synamp is a spin-off of Utrecht University.
Read the full FD article in Dutch.
Link to the LS@W buzz item about Venture Challenge Fall 2016 winner.